



TEM-060-039C CTR Sign-Off Sheet

CLINICAL TRIAL REPORT SIGN-OFF SHEET

Trial title: A multi-site, Phase I/II, 2-part, dose-escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19 using different dosing regimens in healthy and immunocompromised adults

Trial number: BNT162-01


Report type: Interim

Report version/Date: 3.0 / 20 March 2021

Name, role, affiliation	Date (DD MMM YYYY)	Signature (Hand written)
<u>Sponsor signatories</u>		
Elizabeth Adams, MD, Senior Medical Director, BioNTech US, Inc.	_____	_____
Stefan Liebscher, PhD, MSc Responsible Statistician, Dr Liebscher Consulting, Germany	_____	_____

The sponsor signatories confirm that this report i) has been prepared, reviewed, and approved in accordance with the sponsor's standard operating procedures, ii) that the report is accurate, scientifically sound, and adequately presents all relevant information, iii) that documentation of this process is filed in the trial master file, and iv) that they approve the document.

Coordinating investigator
Dr. Dr. med. Armin Schultz,
CRS Clinical Research Services
Mannheim GmbH, Germany

22 MAR 2021 

The coordinating investigator confirms i) that he has reviewed the report, ii) that the report is accurate, scientifically sound, and adequately presents all relevant information, and iii) that he approves the document.

090177e1969715a8\Approved\Approved On: 23-Mar-2021 06:33 (GMT)